Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker BNGO
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 10, 2026 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Sep 14, 2026 | BNGO Bionano Genomics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 10, 2026 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 24, 2026 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 5, 2026 | BNGO Bionano Genomics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 28, 2026 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| May 14, 2026 | BNGO Bionano Genomics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 13, 2026 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 6, 2026 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| May 6, 2026 | BNGO Bionano Genomics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 23, 2026 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 12, 2026 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 13, 2025 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Sep 18, 2025 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Sep 18, 2025 | BNGO Bionano Genomics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 14, 2025 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 18, 2025 | BNGO Bionano Genomics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K/A | 8-K ↗ |
| Jun 13, 2025 | BNGO Bionano Genomics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 13, 2025 | BNGO Bionano Genomics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 14, 2025 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 31, 2025 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 21, 2025 | BNGO Bionano Genomics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 10, 2025 | BNGO Bionano Genomics, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 27, 2025 | BNGO Bionano Genomics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 27, 2025 | BNGO Bionano Genomics, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Jan 27, 2025 | BNGO Bionano Genomics, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Jan 16, 2025 | BNGO Bionano Genomics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jan 13, 2025 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 6, 2025 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jan 6, 2025 | BNGO Bionano Genomics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 6, 2025 | BNGO Bionano Genomics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 3, 2025 | BNGO Bionano Genomics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 3, 2025 | BNGO Bionano Genomics, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jan 3, 2025 | BNGO Bionano Genomics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Dec 2, 2024 | BNGO Bionano Genomics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Nov 13, 2024 | BNGO Bionano Genomics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 31, 2024 | BNGO Bionano Genomics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 31, 2024 | BNGO Bionano Genomics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 31, 2024 | BNGO Bionano Genomics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
39 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances